Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 6/20 | 0.33 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 5/20 | 0.32 |
| ▸ | GSR | P00390 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22436678 | 0.76 | THRA (0.38) | THRATHRB | |
| SCHEMBL22437490 | 0.76 | NPC1 (0.31) | LMNASMN1; SMN2 | |
| SCHEMBL22436736 | 0.76 | HCAR2 (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL22436699 | 0.74 | LMNA (0.32) | LMNASMN1; SMN2 | |
| SCHEMBL22436659 | 0.74 | HTR2A (0.31) | LMNA | |
| SCHEMBL22436689 | 0.74 | KMT2A (0.47) | THRATHRBLMNASMN1; SMN2 | |
| SCHEMBL22436758 | 0.74 | HTR2A (0.31) | SMN1; SMN2 | |
| SCHEMBL22436781 | 0.73 | SMN1; SMN2 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL22436665 | 0.72 | GAA (0.39) | LMNASMN1; SMN2 | |
| SCHEMBL19635556 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891404-B2 | Substituted macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-06 | — | — | US | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230112244-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-09-13 | — | — | US | disclosed |
| CN-111757884-A | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3710451-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230112244-A1 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | FOXM1, CCND2, CCNI | THRA 618/4885L3MBTL4 1912/4885THRB 922/4885 |
| US-11891404-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | THRA 618/4885L3MBTL4 1912/4885THRB 922/4885 |
| US-11440923-B2 | Substituted macrocyclic indole derivatives | FOXM1, CCND2, CCNI | THRA 618/4885L3MBTL4 1912/4885THRB 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.